copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Spinogenix is pioneering therapeutics that restore synapses to improve . . . Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X Syndrome and many others
FDA clears expanded access program for SPG302 in ALS patients Spinogenix has received clearance from the U S Food and Drug Administration (FDA) to launch an expanded access program (EAP) for SPG302, its oral treatment for amyotrophic lateral sclerosis (ALS)
Spinogenix Launches Phase II Trial for Synaptic Regenerative Therapy in . . . Spinogenix announced open enrollment for its Phase II trial of SPG302, the first synaptic regenerative therapy for schizophrenia According to the company, the launch of the Phase II trial comes amid the FDA’s clearance of an Investigational New Drug Application for the treatment